Latest news with #Flovent
Yahoo
30-04-2025
- Health
- Yahoo
Children impacted as asthma inhaler removed from market
More children stopped using steroid inhalers to control their asthma after a manufacturer discontinued a popular inhaler, a new study says. In 2024, GlaxoSmithKline withdrew Flovent from the market. The inhaler was commonly prescribed to prevent asthma attacks in children. The pharma company continued to sell a chemically identical "authorized generic," but some families reportedly had trouble getting this drug because their insurance either didn't cover it or required higher out-of-pocket costs, researchers reported April 26 in the Journal of the American Medical Association. As a result, children were 6 percentage points more likely to have no steroid inhaler in hand to prevent an asthma attack, results show. Asthma inhaler access dropped from nearly 41% to nearly 35% between 2021 and 2023 among patients 18 and younger prescribed Flovent (fluticasone), researchers found. By comparison, young asthma patients prescribed other inhaled steroids had about the same access to an inhaler, at a consistent level around 38%, results show. "Our findings suggest the withdrawal of Flovent disrupted inhaled steroid therapy in children, potentially increasing their risk of asthma attacks," lead researcher Dr. Kao-Ping Chua, a pediatrician at the University of Michigan Health C.S. Mott Children's Hospital, said in a news release. Researchers said Flovent was likely pulled from the market due to changes in rebates that manufacturers must pay to Medicaid programs to obtain drug coverage. Historically, these rebates were capped, but the American Rescue Plan Act of 2021 eliminated this cap in January 2024, researchers said. Eliminating the cap would have resulted in rebates that exceeded Flovent's sales price because GSK had previously increased the drug's price rapidly, researchers said. That exposed them to a rebate that applies when increases in a drug's price outpaces inflation. "Our findings suggest that the elimination of the Medicaid rebate cap had unintended consequences for children with asthma," Chua said. He noted that other drugs also have triggered the rebate cap, including meds for diabetes and infections. "If other brand name drugs are withdrawn due to elimination of the rebate cap, policymakers should proactively implement interventions to prevent therapy disruptions, such as ensuring insurer coverage of alternative drugs," Chua said. More information KFF has more on the elimination of the Medicaid prescription drug rebate cap. Copyright © 2025 HealthDay. All rights reserved.
Yahoo
06-02-2025
- Business
- Yahoo
Arizona says GlaxoSmithKline's greed endangered kids with asthma
Arizona sued drug manufacturer GlaxoSmithKline over what it calls deceptive practices involving the inhaled corticosteroid Flovent that endangered asthma patients. The lawsuit filed Thursday in Maricopa County Superior Court by Arizona Attorney General Kris Mayes, citing the Arizona Consumer Fraud Act, says that the London-based multinational company was motivated by greed when it discontinued a widely used medication, Flovent (fluticasone propionate) and replaced it with an identical authorized generic version "as part of a calculated scheme to avoid paying Medicaid rebates tied to years of price inflation." GlaxoSmithKline officials on Thursday did not immediately respond to a request for comment. Until it was discontinued in 2023, Flovent was one of the most widely prescribed asthma medications in the country, and more than a million Arizonans relied on it, Mayes' office says. It had been available as a prescription metered-dose inhaler (Flovent HFA) and a dry powder inhaler (Flovent Diskus). The switch to the identical generic version of both the metered dose and dry powder inhalers made by Prasco was deceptive on the part of GlaxoSmithKline and bad for some patients whose insurance did not pay for the generic version of the drug and who did not get the same health benefits from using other brands of inhalers, according to the lawsuit. The switch was bad for taxpayers who lost out on rebates to Medicaid, a government health insurance program primarily for low-income people, the 22-page legal action says. The state's lawsuit says GlaxoSmithKline discontinued Flovent due to greed. While it was still on the market, the company, over time, raised the price far beyond inflation, making billions of dollars from Medicaid and private consumers. When the company faced the possibility of owing Medicaid reimbursements for those excessive price hikes, it stopped making Flovent, the lawsuit says, "GSK put corporate greed ahead of the health and safety of Arizona's families and children," Mayes said in a news release. "Their manipulation of the system has left countless patients without access to life-saving medication, caused a spike in emergency room visits, and likely contributed to preventable deaths. My office will not stand by while corporations put profit ahead of the health of children." A provision of the American Rescue Plan removed a cap on Medicaid rebates on Jan. 1, 2024, which was the same day that GlaxoSmithKline discontinued Flovent. By reclassifying a chemical drug under a different name and label, GlaxoSmithKline avoided rebate obligations tied to the Flovent price inflation, the lawsuit says. "It raised the price so much that, with the removal of the rebate cap, GSK was faced with the prospect of having to pay more to Medicaid in rebates than it would earn from sales of the drug to Medicaid," the lawsuit says. "GSK could have avoided such significant rebates by reducing Flovent's price, and thus reducing the amount of price inflation since Flovent's introduction. But GSK chose not to reduce Flovent's price." The scheme allowed GSK to continue charging high prices while evading its legal obligations to taxpayers under Medicaid, leaving families and the public to bear the burden, the news release from Mayes' office says. The lawsuit, her office says, seeks to hold GSK accountable for violating laws that protect consumers from deceptive and unfair practices. Some Arizona health providers say they witnessed firsthand how discontinuing Flovent resulted in serious health consequences for children with asthma. 'My colleagues and I saw firsthand ... what harm this caused to some of our pediatric patients with asthma. We had patients coming into our emergency departments and admitted to our pediatric intensive care units with severe asthma attacks because they were not taking their controller medication (Flovent),' Dr. Rahul Chawla, a pediatric emergency department physician at Banner Thunderbird Medical Center in Glendale, said in a news release. 'The patients and their families either couldn't obtain Flovent from pharmacies since they did not have it, or their parents could not afford to pay for it out of pocket since the new generic form was not covered.' Reach health care reporter Stephanie Innes at or follow her on X, formerly Twitter: @stephanieinnes. This article originally appeared on Arizona Republic: Arizona Attorney General Kris Mayes sues GlaxoSmithKline over Flovent
